- Vaccitech plc (NASDAQ:VACC) announced topline interim data from the HPV001 Phase 1b/2 clinical trial of VTP-200 in women with low-grade cervical human papillomavirus (HPV) lesions.
- “These interim data are a promising step in the right direction, and we look forward to seeing the final data in early 2024,” said Bill Enright, CEO of Vaccitech.
- Data from the first 58 women enrolled who reached their 6-month timepoint in the HPV001 placebo-controlled study were reviewed internally, and the trial will continue as planned to the 12-month primary endpoint.
- Also Read: Vaccitech’s Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens.
- Immunogenicity results showed high responses, defined as an average greater than 1,000 spot-forming units per million peripheral blood mononuclear cells in an ELISPOT assay, especially to the E1, E2, and E6 antigens.
- VTP-200 was generally well-tolerated with no product-related grade 3 unsolicited events and no product-related SAEs.
- These interim data will be presented orally at the upcoming International Papillomavirus Conference in Washington D.C., taking place 17-21 April 2023.
- Price Action: VACC shares are down 4.35% at $2.86 on the last check Monday.
Mizuho Maintains Buy on Tesla, Lowers Price Target to $250
Mizuho analyst Vijay Rakesh maintains Tesla (NASDAQ:TSLA) with a Buy and lowers the price target from $285 to $250.
